Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 12 Prostatic Neoplasms 11 Oropharyngeal Neoplasms 10 Lung Neoplasms 10 Carcinoma, Non-Small-Cell Lung 10 Breast Neoplasms 9 Glioma 8 Urinary Bladder Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Esophageal Neoplasms 6 Neoplasm Metastasis 5 Mouth Neoplasms 5 Carcinoma 5 Burkitt Lymphoma 5 Astrocytoma 5 Sarcoma 4 Pancreatic Neoplasms 4 Laryngeal Neoplasms 4 Gliosarcoma 4 Carcinoma, Hepatocellular 4 Brain Neoplasms 4 Adenocarcinoma of Lung 4 Adenocarcinoma Of Esophagus 4 Uterine Cervical Neoplasms 3 Triple Negative Breast Neoplasms 3 Stomach Neoplasms 3 Rhabdomyosarcoma, Embryonal 3 Rhabdomyosarcoma 3 Rectal Neoplasms 3 Neoplasms 3

Interventions

Cyclophosphamide 26 fludarabine 18 Dexamethasone 17 pembrolizumab 12 Rituximab 11 Etoposide 10 venetoclax 9 pomalidomide 9 Gemcitabine 9 fludarabine phosphate 7 daratumumab 7 Lenalidomide 7 Bortezomib 7 carfilzomib 6 obinutuzumab 5 glofitamab 5 Vincristine 5 Temozolomide 5 Prednisone 5 Nivolumab 5 Immunotherapy, Adoptive 5 Cisplatin 5 Calcium Dobesilate 5 selinexor 4 cemiplimab 4 Doxorubicin 4 Cytarabine 4 Carboplatin 4 zanubrutinib 3 ruxolitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Radiation × 90 days × Clear all

NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡